Article thumbnail

Clinical Grade iPS Cells: Need for Versatile Small Molecules and Optimal Cell Sources

By Yan-Ling Wu, Ganesh N. Pandian, Yan-Ping Ding, Wen Zhang, Yoshimasa Tanaka and Hiroshi Sugiyama

Abstract

Adult mammals possess limited ability to regenerate their lost tissues or organs. The epoch-making strategy of inducing pluripotency in somatic cells incorporates multiple applications in regenerative medicine. However, concerns about the clinical translation of induced pluripotent stem (iPS) cells still exist because of the occurrence of aberrancies, even in genome integration-free methods. As cellular reprogramming is multi-gene-oriented, versatile, bioactive small molecules could concomitantly modulate the transcriptional machinery and aid the generation of clinical grade iPS cells. The availability of optimal cell sources has additional influence on the clinical translation of iPS cells. Herein we provide a critical overview of methods and cell sources available for iPS cell production. We think the review will be a useful resource for researchers who aim to develop small molecules for speeding up the journey of iPS cells from the laboratory to the clinic

Publisher: Elsevier Ltd.
Year: 2013
DOI identifier: 10.1016/j.chembiol.2013.09.016
OAI identifier:
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • https://s3.amazonaws.com/prod-... (external link)
  • https://s3-eu-west-1.amazonaws... (external link)
  • Suggested articles


    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.